Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Cara Therapeutics, Inc. (CARA : NSDQ)

• Company Description    Cara Therapeutics, Inc. is a biopharmaceutical company. The company is focused on developing and commercializing new chemical entities designed to alleviate pain. Cara Therapeutics, Inc. is based in Shelton, United States. Number of Employees: 106

• Price / Volume Information    Yesterday's Closing Price: $3.09 Daily Weekly Monthly 20 Day Moving Average: 786,268 shares Shares Outstanding: 53.97 (millions) Market Capitalization: $166.78 (millions) Beta: 0.87 52 Week High: $12.98 52 Week Low: $2.99 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -28.97% -31.66% 12 Week -51.64% -55.11% Year To Date -71.23% -73.83%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 107 ELM STREET 9TH FLOOR - STAMFORD,CT 06902 USA ph: 203-406-3700 fax: 203-567-1510 investor@caratherapeutics.com http://www.caratherapeutics.com

• General Corporate Information    Officers Christopher Posner - Chief Executive Officer and President Ryan Maynard - Chief Financial Officer Martin Vogelbaum - Director Harrison M. Bains - Director Jeffrey Ives - Director Peer Information Cara Therapeutics, Inc. (CORR.) Cara Therapeutics, Inc. (RSPI) Cara Therapeutics, Inc. (CGXP) Cara Therapeutics, Inc. (BGEN) Cara Therapeutics, Inc. (GTBP) Cara Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 140755109 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/23 Next Expected EPS Date: 08/14/23 Share - Related Items Shares Outstanding: 53.97 Most Recent Split Date: (:1) Beta: 0.87 Market Capitalization: $166.78 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.55 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.89 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/14/23

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.22 Price/Cash Flow: - Price / Sales: 3.86 EPS Growth vs. Year Ago Period: 5.77% vs. Previous Quarter: 12.50% Sales Growth vs. Year Ago Period: 28.71% vs. Previous Quarter: 89.05% ROE 03/31/23 - -49.31 12/31/22 - -45.46 09/30/22 - -43.13 ROA 03/31/23 - -43.52 12/31/22 - -40.40 09/30/22 - -38.87 Current Ratio 03/31/23 - 8.55 12/31/22 - 7.20 09/30/22 - 6.63 Quick Ratio 03/31/23 - 8.34 12/31/22 - 7.10 09/30/22 - 6.56 Operating Margin 03/31/23 - -195.16 12/31/22 - -204.16 09/30/22 - -224.51 Net Margin 03/31/23 - -195.16 12/31/22 - -204.16 09/30/22 - -224.51 Pre-Tax Margin 03/31/23 - -195.16 12/31/22 - -204.16 09/30/22 - -224.51 Book Value 03/31/23 - 2.53 12/31/22 - 2.95 09/30/22 - 3.44 Inventory Turnover 03/31/23 - 2.78 12/31/22 - 3.03 09/30/22 - 2.10 Debt-to-Equity 03/31/23 - 0.00 12/31/22 - 0.00 09/30/22 - 0.00 Debt-to-Capital 03/31/23 - 0.00 12/31/22 - 0.00 09/30/22 - 0.00

Powered by Zacks Investment Research ©